Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2010 Mar 1.

Published in final edited form as: Biochem Pharmacol. 2008 Nov 25;77(5):835–844. doi: 10.1016/j.bcp.2008.11.017

Fig. 4 — Aspirin-treated and washed human platelets were stimulated with 500 μM AYPGKF, 10 μM SFLLRN or 0.2 U/ml Thrombin at 37°C while stirring. Platelet samples were incubated with 20 μg/ml exoenzyme C3 Transferase at 37°C for 4 hrs before the addition of agonists. Platelet shape change (A) aggregation (B) and secretion (C and D) were measured in a Lumi aggregometer. The tracings are representative of data from at least three independent experiments. The secretion data in panel D were normalized to the maximum secretion (taken as 100%).

Fig. 4 — Aspirin-treated and washed human platelets were stimulated with 500 μM AYPGKF, 10 μM SFLLRN or 0.2 U/ml Thrombin at 37°C while stirring. Platelet samples were incubated with 20 μg/ml exoenzyme C3 Transferase at 37°C for 4 hrs before the addition of agonists. Platelet shape change (A) aggregation (B) and secretion (C and D) were measured in a Lumi aggregometer. The tracings are representative of data from at least three independent experiments. The secretion data in panel D were normalized to the maximum secretion (taken as 100%).